Peptonic Medical AB’s Reconstruction plan becomes legally binding and the reconstruction is concluded

Peptonic Medical’s court-confirmed reconstruction plan has become legally binding, concluding the corporate reconstruction and triggering implementation of a directed set-off issue for certain creditors and a rights issue to existing shareholders. The rights issue totals SEK 15 million (minimum SEK 10 million in subscription commitments/guarantees), comprising up to 93,374,091 units (each unit = 100 shares + 100 TO6 warrants) at SEK 0.16 per unit (SEK 0.0016 per share), expected proceeds ~SEK 14.9m before estimated issue costs of ~SEK 1.7m. The measures are conditional on permits from the Inspectorate of Strategic Products and takeover-exemption confirmations; warrants (TO6) can be exercised 1–12 June 2026 with an exercise price equal to 70% of VWAP 18–29 May 2026 (not below quota value). The plan provides immediate debt settlement pathways and short-term financing but is dilutive and subject to regulatory approvals and tight completion timelines.

Analysis

Market structure: Creditors who accept set‑off and guarantors (who provide the ≥SEK10m in commitments) are the primary beneficiaries — they convert distressed claims into equity/warrants and dilute legacy holders. Existing retail shareholders are the clear losers: the rights issue price (SEK0.0016/share) and potential issuance of up to ~9.34bn shares implies >99% theoretical dilution risk if fully taken. Competitive dynamics favor larger OTC women’s-health incumbents (global consumer-health names) who can parry Peptonic’s U.S./EU expansion while Peptonic resets capital structure.

Risk assessment: The binary near‑term tail risks are (1) ISP denial or takeover‑exemptions refusal within ~60 days and (2) failure to complete issues by the two‑month deadline — either would likely trigger bankruptcy (30–50% downside tail). Immediate (days): share volatility and trading halts; short‑term (weeks/months): subscription and guarantee confirmations around record date 9 Jan 2026; long term (12–24 months): success depends on SEK15m runway and conversion of warrants (exercise window 1–12 Jun 2026) to fund U.S. growth. Hidden dependencies include creditor appetite for equity vs cash and legal/exemption timing with ISP.

Trade implications: Tactical direct play — avoid outright long unless objective proof of ≥SEK10m in firm commitments; if commitments ≥75% and independent guarantees confirmed, consider a speculative 1–2% long in Peptonic equity post‑prospectus, otherwise a small short (0.5–1% portfolio) into the issuance. Pair trade — long JNJ or PG (1–2% each) vs a short basket of Spotlight small‑cap Scandinavian medtechs (<SEK50m market cap, negative EBITDA) to capture structural flight to scale. Options: for experienced accounts, buy OTM call spreads on Peptonic warrants/TO6 post‑allocation or buy protective puts on any pre‑issue long — target horizon May–Jun 2026 around VWAP calculation.

Contrarian view: Consensus underestimates that a successful SEK15m raise plus warrant exercise (70% VWAP floor) can stabilize operations and create >2x equity upside if revenue growth in U.S. accelerates 30–50% YoY; the market may be overpricing bankruptcy risk if guarantees are credible. Historical reconstructions show median recovery for operating medtechs with validated OTC products is 0.5–3x over 12–24 months — so payoff asymmetry exists for disciplined, size‑limited speculative buys post‑prospectus. Key unintended consequence: heavy retail participation in rights could create secondary volatility and residual legal disputes over ISP exemptions — set strict stop‑losses (e.g., VWAP breach thresholds) and trigger-based position sizing.

Key Decisions for Investors

• If you have access to the EU Growth Prospectus, establish a speculative long (1–2% portfolio) in Peptonic Medical (Spotlight‑listed) only after independent verification of ≥SEK10m in firm subscription commitments and guarantees; reduce or exit if commitments <SEK10m within 14 days of prospectus publication.
• If prospectus/ISP outcomes are unclear, initiate a short (0.5–1% portfolio) in Peptonic ahead of the two‑month issue deadline; cover immediately if the company confirms full subscription ≥75% or if warrants TO6 are listed and trade above implied fair value (implied conversion value >SEK0.005/share).
• Implement a pair trade: long 1–2% each in defensive consumer health majors JNJ and PG, funded by a 1–2% short position in a basket of Spotlight small‑cap Swedish medtechs (screen: market cap <SEK50m, negative EBITDA) to hedge industry dispersion over next 6–12 months.
• For options traders: plan a calendar trade around warrant exercise window (1–12 Jun 2026) — buy Jun 2026 call spreads on Peptonic warrants/TO6 if listed, or buy protective puts on any pre‑issue equity long; size to limit max loss to 0.5–1% of portfolio.
• Hard triggers to act: (A) if ISP denies permits or takeover exemptions within 60 days, close longs and add shorts; (B) if subscription commitments ≥SEK10m and guarantees confirmed within 30 days, trim shorts and consider staged buys with a stop if VWAP < SEK0.002 over 5 trading days.